06:39 AM EDT, 06/17/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that its drug nipocalimab showed "clinically meaningful improvements" in meeting its primary and secondary endpoints as a treatment for adult patients living with Sjogren's disease during a phase 2 study.

According to the company, the patients in a 163-person study who received nipocalimab 15 mg/kg showed improvement of more than 70% in meeting the primary endpoint of decreasing disease activity in 11 organs compared with those who were given a placebo.

Sjogren's is a serious, chronic autoimmune disease.

Nipocalimab is an intravenously administered potential treatment. One researcher in the study said the data "establish proof of concept" for the drug and encourage further clinical testing.

Price: 145.29, Change: -0.25, Percent Change: -0.17